West Penn Hospital

Summary

West Penn Hospital is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Ovarian Cancer, Lung Cancer, Breast Cancer, Cancer, Fallopian Tube Cancer and other specialties. West Penn Hospital is involved with conducting 270 clinical trials across 464 conditions. There are 23 research doctors associated with this hospital, such as Thomas Krivak, Sarah Crafton, Gene G. Finley, and Dulabh Monga, MD.

Top PIs

Clinical Trials running at West Penn Hospital

Ovarian Cancer

Skin Cancer

Bladder Cancer

Bladder Carcinoma

Pancreatic Cancer

Kidney Cancer

Endometrial Cancer

Colorectal Cancer

Multiple Myeloma

Breast Cancer

Heated Chemotherapy + Niraparib

for Ovarian Cancer

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at the time of iCRS (iCRS must achieve no gross residual disease or no disease \>1.0 cm in largest diameter) to receive HIPEC or no HIPEC. Patients randomized to HIPEC Arm will receive a single dose of cisplatin (100mg/m2 IP over 90 minutes at 42 C) as HIPEC. After postoperative recovery patients will receive standard post-operative platinum-based combination chemotherapy. Patients randomized to surgery only (No HIPEC Arm) will receive postoperative standard chemotherapy after recovery from surgery. Both groups will receive an additional 2-3 cycles of platinum-based combination chemotherapy per standard institutional guidelines +/- bevacizumab for a maximum total of 6 cycles of chemotherapy (neoadjuvant plus post-operative cycles) followed by niraparib individualized dosing +/- bevacizumab until progression or 36 months (if no evidence of disease).

Recruiting

2 awards

Phase 3

Olvi-Vec + Chemotherapy

for Ovarian Cancer

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.

Recruiting

2 awards

Phase 3

7 criteria

IMGN151

for Ovarian Cancer

This trial is testing IMGN151, a new drug, in adults with certain recurrent cancers to see if it is safe, how the body handles it, if it causes immune reactions, and if it can help fight the cancer.

Recruiting

1 award

Phase 1